drugset / Trial / NCT00310544

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

NCT00310544

Phase 2 Completed 73 enrolled Bayer
RandomizedCrossoverSingle-blindDiagnostic

Summary

The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.

Timeline

Start
2006-03
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.1 mmol Intravenous
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.2 mmol Intravenous

Indications